The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Open accessAbstract
Primary triple-negative breast cancers (TNBCs), a tumour type defined by lack of oestrogen receptor, progesterone receptor and ERBB2 gene amplification, represent approximately 16% of all breast cancers. Here we show in 104 TNBC cases that at the time of diagnosis these cancers exhibit a wide and continuous spectrum of genomic evolution, with some having only a handful of coding somatic aberrations in a few pathways, whereas others contain hundreds of coding somatic mutations. High-throughput RNA sequencing (RNA-seq) revealed that only approximately 36% of mutations are expressed. Using deep re-sequencing measurements of allelic abundance for 2,414 somatic mutations, we determine for the first time-to our knowledge-in an epithelial tumour subtype, the relative abundance of clonal frequencies among cases representative of the population. We show that TNBCs vary widely in their clonal frequencies at the time of diagnosis, with the basal subtype of TNBC showing more variation than non-basal TNBC. Although p53 (also known as TP53), PIK3CA and PTEN somatic mutations seem to be clonally dominant compared to other genes, in some tumours their clonal frequencies are incompatible with founder status. Mutations in cytoskeletal, cell shape and motility proteins occurred at lower clonal frequencies, suggesting that they occurred later during tumour progression. Taken together, our results show that understanding the biology and therapeutic responses of patients with TNBC will require the determination of individual tumour clonal genotypes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is estimated that p53 is mutated in approximately 50% of all cancers with 60% of TNBCs bearing mutations in p53 (14, 15);”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [15]
In the citing paper
“It is estimated that p53 is mutated in approximately 50% of all cancers with 60% of TNBCs bearing mutations in p53 (14, 15);”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [15]
In the citing paper
“Approximately 60% of basal TNBCs bear mutations in p53 (15) and ~90% of mutations in p53 occur in the DNA binding domain.”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551
Sørlie, T., Perou, C. M., Tibshirani, R. J., Aas, T., Geisler, S. B., Johnsen, H., Hastie, T. J., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 11,506
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Self-citationSupervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S. C. Y., Voduc, D. K., Vickery, T. L., Davies, S. R., Fauron, C. M. ‐., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,818
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
The Mutational Landscape of Head and Neck Squamous Cell Carcinoma
Stransky, N., Egloff, A. M., Tward, A. D., Kostic, A. D., Cibulskis, K., Sivachenko, A., Kryukov, G. V., Lawrence, M. S., Sougnez, C. L., McKenna, A., et al. (2011) · Science · doi:10.1126/science.1208130 · Cited by 2,541
Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1
Agrawal, N., Frederick, M. J., Pickering, C. R., Bettegowda, C., Chang, K., Li, R. J., Fakhry, C., Xie, T., Zhang, J., Wang, J., et al. (2011) · Science · doi:10.1126/science.1206923 · Cited by 1,697
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Morin, R. D., Mendez-Lago, M., Mungall, A. J., Goya, R., Mungall, K. L., Corbett, R. D., Johnson, N. A., Severson, T. M., Chiu, R., Field, M., et al. (2011) · Nature · doi:10.1038/nature10351 · Cited by 1,614
Self-citationGenome remodelling in a basal-like breast cancer metastasis and xenograft
Ding, L., Ellis, M. J., Li, S., Larson, D. E., Chen, K., Wallis, J. W., Harris, C. C., McLellan, M. D., Fulton, R. S., Fulton, L., et al. (2010) · Nature · doi:10.1038/nature08989 · Cited by 1,144
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 1,003
Nguyen, L. V., Makarem, M., Carles, A., Moksa, M., Kannan, N., Pandoh, P. K., Eirew, P. D., Osako, T., Kardel, M., Cheung, A. M. S., et al. (2014) · Cell stem cell · doi:10.1016/j.stem.2013.12.011 · Cited by 68
Self-citationStover, D. G., Coloff, J. L., Barry, W. T., Brugge, J. S., Winer, E. P., & Selfors, L. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0471 · Cited by 69
Validated biomarkers: The key to precision treatment in patients with breast cancer
Duffy, M. J., O’Donovan, N., McDermott, E. W. M., & Crown, J. P. (2016) · The Breast · doi:10.1016/j.breast.2016.07.009 · Cited by 73
Precision medicine in breast cancer: reality or utopia?
Bettaı̈eb, A., Paul, C., Plenchette, S., Shan, J., Chouchane, L., & Ghiringhelli, F. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1239-z · Cited by 69
Rodríguez‐Bautista, R., Ortega-Gómez, A., Hidalgo‐Miranda, A., Zentella‐Dehesa, A., Villarreal-Garza, C. M., Ávila‐Moreno, F., & Arrieta, O. G. (2018) · Clinical Epigenetics · doi:10.1186/s13148-018-0514-z · Cited by 69
Gautam, P., Karhinen, L., Szwajda, A., Jha, S. K., Yadav, B., Aittokallio, T. A., & Wennerberg, K. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0517-3 · Cited by 66
Comparing somatic mutation-callers: beyond Venn diagrams
Kim, S. Y., & Speed, T. P. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-189 · Cited by 66
The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer
Boyle, D. P., McArt, D. G., Irwin, G. W., Wilhelm-Benartzi, C. S., Lioe, T. F., Sebastián, E., McQuaid, S., Hamilton, P. W., James, J. A., Mullan, P. B., et al. (2014) · Histopathology · doi:10.1111/his.12398 · Cited by 67
Severson, T., Peeters, J. K., Majewski, I. J., Michaut, M., Bosma, A. R., Schouten, P. C., Chin, S., Pereira, B., Goldgraben, M. A., Bismeijer, T., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.04.011 · Cited by 67
Self-citationGenome Aberrations in Canine Mammary Carcinomas and Their Detection in Cell-Free Plasma DNA
Beck, J., Hennecke, S., Bornemann-Kolatzki, K., Urnovitz, H. B., Neumann, S., Ströbel, P., Kaup, F., Brenig, B., & Schütz, E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075485 · Cited by 65
Kim, J., Park, K., Jung, H. H., Lee, E., Cho, E. Y., Lee, K. H., Bae, S. Y., Lee, S. K., Kim, S. W., Lee, J. E., et al. (2016) · Cancer Research and Treatment · doi:10.4143/crt.2015.430 · Cited by 69
How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case
Appierto, V., Cosimo, S. D., Reduzzi, C., Pala, V., Cappelletti, V., & Daidone, M. G. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.04.007 · Cited by 69
Emerging therapies for breast cancer
Hu, X., Huang, W., & Fan, M. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0466-3 · Cited by 71
Baslan, T., Kendall, J., Volyanskyy, K. Y., McNamara, K. L., Cox, H., D'Italia, S., Ambrosio, F. J., Riggs, M. G., Rodgers, L., Leotta, A., et al. (2020) · eLife · doi:10.7554/elife.51480 · Cited by 67
Self-citationWu, X., Zahari, M. S., Ma, B., Liu, R., Renuse, S., Sahasrabuddhe, N. A., Chen, L., Chaerkady, R., Kim, M., Zhong, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5020 · Cited by 66
Spinella, J.-F., Mehanna, P., Vidal, R. O., Saillour, V., Cassart, P., Richer, C., Ouimet, M., Healy, J., & Sinnett, D. (2016) · BMC Genomics · doi:10.1186/s12864-016-3281-2 · Cited by 71
Nagata, Y., Makishima, H., Kerr, C. M., Przychodzen, B. P., Aly, M. M., Goyal, A., Awada, H. K., Asad, M., Kuzmanovic, T., Suzuki, H., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13001-y · Cited by 69
Zhang, Q., Li, L., & Jing, D. (2020) · Oncology Reports · doi:10.3892/or.2020.7770 · Cited by 66
Ansari‐Pour, N., Zheng, Y., Yoshimatsu, T. F., Sanni, A., Ajani, M., Reynier, J.-B., Tapinos, A., Pitt, J. J., Dentro, S. C., Woodard, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27079-w · Cited by 66
Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics
Landau, D. A., & Wu, C. J. (2013) · Genome Medicine · doi:10.1186/gm451 · Cited by 70
Progress in the clinical detection of heterogeneity in breast cancer
Song, J., Chen, C., Yuan, J., & Sun, S. (2016) · Cancer Medicine · doi:10.1002/cam4.943 · Cited by 66
DNA damage repair in breast cancer and its therapeutic implications
Ali, R., Rakha, E. A., Madhusudan, S., & Bryant, H. E. (2016) · Pathology · doi:10.1016/j.pathol.2016.11.002 · Cited by 66
HER2 somatic mutations are associated with poor survival in HER2‐negative breast cancers
Wang, T., Xu, Y., Sheng, S., Yuan, H., Ouyang, T., Li, J., Wang, T., Fan, Z., Fan, T., Lin, B., et al. (2017) · Cancer Science · doi:10.1111/cas.13182 · Cited by 66
Sikandar, S. S., Kuo, A. H., Tomer Kalisky, C., Cai, S., Zabala, M., Hsieh, R. W., Lobo, N. A., Scheeren, F. A., Sim, S., Qian, D., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01666-2 · Cited by 66
van Gijn, S. E., Wierenga, E., van den Tempel, N., Kok, Y. P., Heijink, A. M., Spierings, D. C. J., Foijer, F., van Vugt, M. A. T. M., & Fehrmann, R. S. N. (2018) · Oncogene · doi:10.1038/s41388-018-0470-2 · Cited by 64
Rocca, A., Braga, L., Volpe, M. C., Maiocchi, S., & Generali, D. (2022) · Cancers · doi:10.3390/cancers14215306 · Cited by 71
Wang, X., Collet, L., Rediti, M., Debien, V., Caluwé, A. D., Venet, D., Romano, E., Rothé, F., Sotiriou, C. P., & Buisseret, L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12030953 · Cited by 69
The evolution of the unstable cancer genome
Burrell, R. A., & Swanton, C. (2014) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2013.11.011 · Cited by 66
Yang, G., Zhong, H., Ko, C.-N., Wong, S.-Y., Vellaisamy, K., Ye, M., Ma, D., & Leung, C. (2018) · Chemical Communications · doi:10.1039/c7cc09384e · Cited by 65
Jang, B., Han, W., & Kim, I. A. (2019) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2019.11.003 · Cited by 64
DNA damage response inhibitors: An avenue for TNBC treatment
Jin, J., Tao, Z., Cao, J., Li, T., & Hu, X. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188521 · Cited by 60
You, K. S., Yi, Y. W., Cho, J., Park, J., & Seong, Y. (2021) · Pharmaceuticals · doi:10.3390/ph14060589 · Cited by 64
Neelakantan, D., Drasin, D. J., & Ford, H. L. (2014) · Cell Adhesion & Migration · doi:10.4161/19336918.2014.972761 · Cited by 64
Guerini‐Rocco, E., Piscuoglio, S., Ng, C. K. Y., Geyer, F. C., Filippo, M. R. D., Eberle, C. A., Akram, M. M., Fusco, N., Ichihara, S., Sakr, R. A., et al. (2016) · The Journal of Pathology · doi:10.1002/path.4691 · Cited by 65
Harao, M., Forget, M., Roszik, J., Gao, H., Babiera, G. V., Krishnamurthy, S., Chacon, J. A., Li, S., Mittendorf, E. A., DeSnyder, S. M., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0364 · Cited by 64
Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling
WICKI, A. N., Mandalà, M., Massi, D., Taverna, D., Tang, H., Hemmings, B. A., & Xue, G. (2016) · Physiological Reviews · doi:10.1152/physrev.00024.2015 · Cited by 64
siRNA-based nanocarriers for targeted drug delivery to control breast cancer
Ashique, S., Almohaywi, B., Haider, N., Yasmin, S., Hussain, A., Mishra, N., & Garg, A. (2022) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2022.100047 · Cited by 68
Prognostic role of PIK 3 CA mutations of cell‐free DNA in early‐stage triple negative breast cancer
Takeshita, T., Yamamoto, Y., Yamamoto‐Ibusuki, M., Inao, T., Sueta, A., Fujiwara, S., Omoto, Y., & Iwase, H. (2015) · Cancer Science · doi:10.1111/cas.12813 · Cited by 64
Mackey, J. R., Pieńkowski, T., Crown, J. P., Sadeghi, S., Martín, M., Chan, A., Saleh, M. N., Sehdev, S. R., Provencher, L., Семиглазов, В. Ф., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw098 · Cited by 63
Self-citationThe Making of a PreCancer Atlas: Promises, Challenges, and Opportunities
Srivastava, S., Ghosh, S., Kagan, J., Mazurchuk, R. V., Boja, E. S., Chuaqui, R. F., Chavarria-Johnson, E., Davidsen, T. M., Eary, J. F., Haim, T., et al. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.06.007 · Cited by 60
Qiao, Y., Quinlan, A. R., Jazaeri, A. A., Verhaak, R. G. W., Wheeler, D. A., & Marth, G. (2014) · Genome biology · doi:10.1186/preaccept-1691129011290725 · Cited by 61
Ademuyiwa, F. O., Gao, F., Street, C., Chen, I., Northfelt, D., Wesolowski, R., Arora, M., Brufsky, A., Dees, E. C., Santa-Maria, C. A., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00500-3 · Cited by 63
Self-citationBłaszczak, E., Miziak, P. A., Odrzywolski, A., Baran, M. T., Gumbarewicz, E., & Stepulak, A. (2025) · Cancers · doi:10.3390/cancers17020228 · Cited by 71
Analysis of different HER ‐2 mutations in breast cancer progression and drug resistance
Sun, Z., Shi, Y., Shen, Y., Cao, L., Zhang, W., & Guan, X. (2015) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12662 · Cited by 64
Molecular Heterogeneity of Triple-Negative Breast Cancer
Abramson, V. G., & Mayer, I. A. (2014) · Current Breast Cancer Reports · doi:10.1007/s12609-014-0152-1 · Cited by 62
Wnt modulates MCL1 to control cell survival in triple negative breast cancer
Yang, L., Perez, A. A., Fujie, S., Warden, C., Li, J., Wang, Y., Yung, B. S., Chen, Y.-R., Liu, X., Zhang, H., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-124 · Cited by 66
Cell to extracellular matrix interactions and their reciprocal nature in cancer
van Dijk, M., Göransson, S., & Strömblad, S. (2013) · Experimental Cell Research · doi:10.1016/j.yexcr.2013.02.006 · Cited by 62
Personalized medicine: Present and future of breast cancer management
Sabatier, R., Gonçalvès, A., & Bertucci, F. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.03.002 · Cited by 65
Subtelomeric p53 binding prevents accumulation of DNA damage at human telomeres
Tutton, S., Azzam, G. A., Stong, N., Vladimirova, O. V., Wiedmer, A., Monteith, J., Beishline, K., Wang, Z., Deng, Z., Riethman, H. C., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201490880 · Cited by 69
Miles, W. O., Lembo, A., Volorio, A., Brachtel, E. F., Tian, B., Sgroi, D. C., Provero, P., & Dyson, N. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0844 · Cited by 64
Predicting and Overcoming Chemotherapeutic Resistance in Breast Cancer
Chun, K., Park, J. H., & Fan, S. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6020-5_4 · Cited by 60
Ritter, J., Zhu, Z., Thai, T. C., Mahadevan, N. R., Mertins, P., Knelson, E. H., Piel, B. P., Han, S., Jaffe, J. D., Carr, S. A., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1310 · Cited by 60
Principles of digital PCR and its applications in current obstetrical and gynecological diseases.
Mao, X., Liu, C., Tong, H., Chen, Y., & Liu, K. (2019) · Europe PMC (PubMed Central) · Cited by 61
Akt Isoforms: A Family Affair in Breast Cancer
Basu, A., & Lambring, C. B. (2021) · Cancers · doi:10.3390/cancers13143445 · Cited by 62
Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions
Hossain, F. M., Majumder, S., David, J., & Miele, L. (2021) · Cancers · doi:10.3390/cancers13153739 · Cited by 62
Rigiracciolo, D. C., Nohata, N., Lappano, R., Cirillo, F., Talia, M., Adame-Garcia, S. R., Arang, N., Lubrano, S., Francesco, E. M. D., Belfiore, A., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02396-0 · Cited by 62
Triple-Negative Breast Cancer: Histopathologic Features, Genomics, and Treatment
Adrada, B. E., Moseley, T. W., Kapoor, M. M., Scoggins, M. E., Patel, M. M., Perez, F., Nia, E. S., Khazai, L., Arribas, E. M., Rauch, G. M., et al. (2023) · Radiographics · doi:10.1148/rg.230034 · Cited by 75
Fan, M., Sethuraman, A., Brown, M., Sun, W., & Pfeffer, L. M. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3040-5 · Cited by 62
Klevebring, D., Rosin, G., Ma, R., Lindberg, J., Czene, K., Kere, J., Fredriksson, I., Bergh, J. C. S., & Hartman, J. (2014) · Breast Cancer Research · doi:10.1186/bcr3687 · Cited by 61
Evaluation and consequences of heterogeneity in the circulating tumor cell compartment
Brouwer, A., Laere, B. D., Peeters, D. J. E., Peeters, M., Salgado, R., Dirix, L. Y., & Laere, S. V. (2016) · Oncotarget · doi:10.18632/oncotarget.8015 · Cited by 64
Wong, S. Q., Li, J., Salemi, R., Sheppard, K. E., Do, H., Tothill, R. W., McArthur, G. A., & Dobrovic, A. (2013) · Scientific Reports · doi:10.1038/srep03494 · Cited by 59
Shanle, E. K., Zhao, Z., Hawse, J. R., Wisinski, K. B., Keleş, S., Yuan, M., & Xu, W. (2013) · Molecular Endocrinology · doi:10.1210/me.2013-1164 · Cited by 62
Molecular Pathways: PI3K Pathway Targets in Triple-Negative Breast Cancers
Gordon, V. L., & Banerji, S. O. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0274 · Cited by 62
Davis, S. J., Sheppard, K. E., Pearson, R. B., Campbell, I., Gorringe, K. L., & Simpson, K. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3433 · Cited by 60
Insights into the Role of Estrogen Receptor β in Triple-Negative Breast Cancer
Sellitto, A., D’Agostino, Y., Alexandrova, E., Lamberti, J., Pecoraro, G., Memoli, D., Rocco, D., Coviello, E., Giurato, G., Nassa, G., et al. (2020) · Cancers · doi:10.3390/cancers12061477 · Cited by 63
Therapeutic Advances in Oncology
Liu, J., Pandya, P., & Afshar, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042008 · Cited by 65
Wu, Y., Sarkissyan, M., Elshimali, Y., & Vadgama, J. V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078259 · Cited by 59
Tilch, E., Seidens, T., Cocciardi, S., Reid, L., Byrne, D. J., Simpson, P. T., Vargas, A. C., Cummings, M. C., Fox, S. B., Lakhani, S. R., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2798-1 · Cited by 59
How integrins control breast biology
Glukhova, M. A., & Streuli, C. H. (2013) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2013.06.010 · Cited by 59
Identifying potential cancer driver genes by genomic data integration
Chen, Y., Hao, J., Jiang, W., He, T., Zhang, X., Jiang, T., & Jiang, R. (2013) · Scientific Reports · doi:10.1038/srep03538 · Cited by 59
Glucocorticoid receptor regulates accurate chromosome segregation and is associated with malignancy
Matthews, L. C., Berry, A. A., Morgan, D. J., Poolman, T. M., Bauer, K., Kramer, F., Spiller, D. G., Richardson, R. V., Chapman, K. E., Farrow, S. N., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411356112 · Cited by 62
Basal-A Triple-Negative Breast Cancer Cells Selectively Rely on RNA Splicing for Survival
Chan, S., Sridhar, P., Kirchner, R., Lock, Y. J., Herbert, Z. T., Buonamici, S., Smith, P. G., Lieberman, J., & Petrocca, F. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0461 · Cited by 59
Self-citationPatel, N., Weekes, D. B., Drosopoulos, K. G., Gazińska, P., Noel, E. E., Rashid, M., Mirza, H., Quist, J., Brasó‐Maristany, F., Mathew, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03283-z · Cited by 63
Qattan, A. T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238905 · Cited by 59
Cha, S., Lee, E., & Won, H. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00303-y · Cited by 56
Current Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast Cancer
Ahn, S. G., Jeong, J., Hong, S. W., & Jung, W. H. (2015) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2015.07.29 · Cited by 58
Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3K pathway
Park, Y. H., Jung, H. H., Ahn, J. S., & Im, Y. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.08.043 · Cited by 58
Genetic heterogeneity in breast cancer: the road to personalized medicine?
Baird, R. D., & Caldas, C. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-151 · Cited by 59
Self-citationHealey, M. A., Hu, R., Beck, A. H., Collins, L. C., Schnitt, S. J., Tamimi, R. M., & Hazra, A. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3089-1 · Cited by 59
FOXA1 mutations in hormone-dependent cancers
Robinson, J. L. L., Holmes, K. A., & Carroll, J. S. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00020 · Cited by 58
Current advances in biomarkers for targeted therapy in triple-negative breast cancer
Fleisher, B., Clarke, C. H., & Ait‐Oudhia, S. (2016) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s114659 · Cited by 60
Transposon mutagenesis identifies genes that cooperate with mutant Pten in breast cancer progression
Rangel, R., Lee, S.-C., Ban, K. H.-K., Guzman‐Rojas, L., Mann, M. B., Newberg, J. Y., Kodama, T., McNoe, L. A., Selvanesan, L., Ward, J. M., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1613859113 · Cited by 58
Kong, P., Chen, L., Yu, M., Tao, J., Liu, J., Wang, Y., Pan, H., Zhou, W., & Wang, S. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1091-y · Cited by 58
Concepts in solid tumor evolution
Sidow, A., & Spies, N. (2015) · Trends in Genetics · doi:10.1016/j.tig.2015.02.001 · Cited by 60
Kvokačková, B., Remšík, J., Jolly, M. K., & Souček, K. (2021) · Cancers · doi:10.3390/cancers13092188 · Cited by 62
Anticancer Activity of Bee Venom Components against Breast Cancer
Kwon, N.-Y., Sung, S.-H., Sung, H.-K., & Park, J.-K. (2022) · Toxins · doi:10.3390/toxins14070460 · Cited by 59
Ades, F., Tryfonidis, K., & Zardavas, D. (2017) · ecancermedicalscience · doi:10.3332/ecancer.2017.746 · Cited by 57
The promise of circulating tumor cell analysis in cancer management
Mateo, J., Gerlinger, M., Rodrigues, D. N., & Bono, J. S. D. (2014) · Genome biology · doi:10.1186/s13059-014-0448-5 · Cited by 56
Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale
Barber, L. J., Davies, M. N., & Gerlinger, M. (2014) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2014.12.001 · Cited by 57
Precision Oncology, Signaling, and Anticancer Agents in Cancer Therapeutics
Advani, D., Sharma, S., Kumari, S., Ambasta, R. K., & Kumar, P. (2021) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621666210308101029 · Cited by 63
Qin, J., Wang, W., Voruganti, S., Wang, H., Zhang, W., & Zhang, R. (2014) · Oncotarget · doi:10.18632/oncotarget.3098 · Cited by 56
Differential and limited expression of mutant alleles in multiple myeloma
Rashid, N. U., Sperling, A. S., Bolli, N., Wedge, D. C., Loo, P. V., Tai, Y., Shammas, M. A., Fulciniti, M., Samur, M., Richardson, P. G. G., et al. (2014) · Blood · doi:10.1182/blood-2014-04-569327 · Cited by 55
Re-Evaluating Clonal Dominance in Cancer Evolution
Burrell, R. A., & Swanton, C. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.04.002 · Cited by 54
Mundt, F., Rajput, S., Li, S., Ruggles, K. V., Mooradian, A. D., Mertins, P., Gillette, M. A., Krug, K., Guo, Z., Hoog, J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1990 · Cited by 57
Subclonal heterogeneity and evolution in breast cancer
Mavrommati, I., Johnson, F., Echeverria, G. V., & Natrajan, R. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00363-0 · Cited by 56
Colomer, R., Miranda, J., Romero-Laorden, N., Hornedo, J., González‐Cortijo, L., Mouron, S. A., Bueno, M. J., Mondéjar, R., & Quintela-Fandiño, M. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102029 · Cited by 57
Application of Metabolomics in Drug Resistant Breast Cancer Research
Shajahan‐Haq, A. N., Cheema, M., & Clarke, R. C. (2015) · Metabolites · doi:10.3390/metabo5010100 · Cited by 56
Sugita, B. M., Gill, M. K., Mahajan, A., Duttargi, A., Kirolikar, S., de Almeida, R. C., Regis, K., Oluwasanmi, O. L., Marchi, F. A., Marian, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13024 · Cited by 55
Wang, J., Song, C., Tang, H., Zhang, C., Tang, J., Li, X., Chen, B., & Xie, X. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0865-y · Cited by 55
Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies
Steenbruggen, T. G., van Ramshorst, M. S., Kok, M., Linn, S. C., Smorenburg, C. H., & Sonke, G. S. (2017) · Drugs · doi:10.1007/s40265-017-0774-5 · Cited by 57
Metadata
- Authors
- Shah, S. P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., Bashashati, A., Prentice, L. M., Khattra, J., Burleigh, A., Yap, D., Bernard, V., McPherson, A., Shumansky, K., Crisan, A., Giuliany, R., Heravi-Moussavi, A., Rosner, J., Lai, D., Birol, I., Varhol, R., Tam, A., Dhalla, N., Zeng, T., Ma, K., Chan, S. K., Griffith, M., Moradian, A., Cheng, S.-W. G., Morin, G. B., Watson, P., Gelmon, K., Chia, S., Chin, S.-F., Curtis, C., Rueda, O. M., Pharoah, P. D., Damaraju, S., Mackey, J., Hoon, K., Harkins, T., Tadigotla, V., Sigaroudinia, M., Gascard, P., Tlsty, T., Costello, J. F., Meyer, I. M., Eaves, C. J., Wasserman, W. W., Jones, S., Huntsman, D., Hirst, M., Caldas, C., Marra, M. A., & Aparicio, S.
- Affiliations
- University of British Columbia (CA)
- Canada's Michael Smith Genome Sciences Centre (CA)
- BC Cancer Agency (CA)
- University of Cambridge (GB)
- University of Southern California (US)
- Cancer Research UK (GB)
- University of Alberta (CA)
- University of California, San Francisco (US)
- Corresponding author
- Shah, Sohrab P.
- Caldas, Carlos
- Marra, Marco A.
- Aparicio, Samuel
- ORCID
- Shah, Sohrab P.
- Roth, Andrew
- Ha, Gavin
- Zhao, Yongjun
- Turashvili, Gulisa
- Ding, Jiarui
- Haffari, Gholamreza
- Bashashati, Ali
- Prentice, Leah M.
- Burleigh, Angela
- Yap, Damian
- McPherson, Andrew
- Crisan, Anamaria
- Rosner, Jamie
- Lai, Daniel
- Varhol, Richard
- Tam, Angela
- Griffith, Malachi
- Moradian, Annie
- Cheng, S.-W. Grace
- Morin, Gregg B.
- Watson, Peter
- Gelmon, Karen
- Chia, Stephen
- Chin, Suet-Feung
- Curtis, Christina
- Rueda, Oscar M.
- Pharoah, Paul D.
- Damaraju, Sambasivarao
- Mackey, John
- Harkins, Timothy
- Gascard, Philippe
- Tlsty, Thea
- Costello, Joseph F.
- Meyer, Irmtraud M.
- Eaves, Connie J.
- Wasserman, Wyeth W.
- Jones, Steven
- Huntsman, David
- Hirst, Martin
- Caldas, Carlos
- Marra, Marco A.
- Aparicio, Samuel
- Venue
- Nature
- Published
- 2012-04-04
- Volume
- 486
- Issue
- 7403
- Pages
- 395-399
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3863681
- OpenAlex
- W2063382533
- Cited by
- 1,967
- References
- 23
- Citations by year
- 2026: 40 · 2025: 61 · 2024: 71 · 2023: 131 · 2022: 132 · 2021: 119 · 2020: 131 · 2019: 120 · 2018: 135 · 2017: 173 · 2016: 179 · 2015: 198 · 2014: 199 · 2013: 201 · 2012: 76
- FWCI
- 71.57
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (submittedVersion)
- eSpace (Curtin University) (submittedVersion)
- Funders
- U.S. Department of Defense
- Memorial Sloan-Kettering Cancer Center
- Canada's Michael Smith Genome Sciences Centre
- Canadian Breast Cancer Research Alliance
- Michael Smith Health Research BC
- Cancer Research UK
- National Institute for Health and Care Research (NF-SI-0611-10154)
- Cure Brain Cancer Foundation
- BC Cancer Foundation
- National Institutes of Health
- Imperial Experimental Cancer Medicine Centre
- BC Cancer Agency
- National Institute of General Medical Sciences (R01GM084875)
- National Institute of Environmental Health Sciences (U01ES017154)
- Congressionally Directed Medical Research Programs
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- triple-negative breast cancer, clonal evolution, somatic mutations, copy number variation, cancer genomics, TP53 mutation, PIK3CA mutation, PTEN mutation, basal subtype, tumor progression, founder mutation, clonal heterogeneity
- MeSH terms
- Alleles, Breast Neoplasms, Clone Cells, DNA Mutational Analysis, Female, Genotype, Humans, Mutation, Reproducibility of Results, Gene Expression Regulation, Neoplastic, Point Mutation, Sequence Analysis, RNA, Disease Progression, Evolution, Molecular, Gene Expression Profiling, INDEL Mutation, DNA Copy Number Variations, Precision Medicine, High-Throughput Nucleotide Sequencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
